Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2019
Event: Completion of the disposition of the DaVita Medical Group (DMG) division.
Key Financial Metrics
- Transaction Value: Aggregate purchase price of $4,340,000,000 paid by the Buyer (Collaborative Care Holdings, LLC, a subsidiary of Optum, Inc.).
- Adjustments: The purchase price is subject to customary adjustments specified in the Purchase Agreement.
- Pro Forma Data: Unaudited pro forma financial statements reflecting the disposition are filed as Exhibit 99.1 for the periods ended March 31, 2019, and December 31, 2018.
- Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period; these are contained in the referenced pro forma exhibits.
Material Changes
DaVita completed the sale of all issued and outstanding equity interests of DaVita Medical Holdings, LLC (the DaVita Medical Group division) to Optum. This transaction finalizes an agreement originally dated December 5, 2017, and subsequently amended in September 2018 and December 2018.
Guidance, Outlook, and Risks
- Use of Proceeds: The filing contains forward-looking statements regarding intentions for the use of net proceeds from the sale, though specific allocation details are not enumerated in the text.
- Risks: Actual results may differ materially due to risks outlined in DaVita's most recent Form 10-Q and subsequent SEC filings.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements based on new information or changed circumstances.
Investor Verification Checklist
- Verify the final purchase price after customary adjustments are applied to the $4.34 billion base amount.
- Review Exhibit 99.1 for unaudited pro forma consolidated balance sheets and income statements to assess the financial impact of the divestiture.
- Examine the joint press release (Exhibit 99.2) for specific details on the strategic rationale and immediate use of proceeds.
- Consult the referenced Form 10-Q for the full list of risk factors applicable to the company post-transaction.